282 related articles for article (PubMed ID: 35059999)
1. Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma.
Piña Y; Yadugiri S; Yeboa DN; Ferguson SD; Forsyth PA; Oliva ICG
Curr Oncol Rep; 2022 Jan; 24(1):43-54. PubMed ID: 35059999
[TBL] [Abstract][Full Text] [Related]
2. Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment.
Steininger J; Gellrich FF; Engellandt K; Meinhardt M; Westphal D; Beissert S; Meier F; Glitza Oliva IC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511202
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and Therapeutic Updates in Leptomeningeal Disease.
Roy-O'Reilly MA; Lanman T; Ruiz A; Rogawski D; Stocksdale B; Nagpal S
Curr Oncol Rep; 2023 Aug; 25(8):937-950. PubMed ID: 37256537
[TBL] [Abstract][Full Text] [Related]
4. Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
Chorti E; Kebir S; Ahmed MS; Keyvani K; Umutlu L; Kanaki T; Zaremba A; Reinboldt-Jockenhoefer F; Knispel S; Gratsias E; Roesch A; Ugurel S; Scheffler B; Schadendorf D; Livingstone E; Meier F; Glas M; Zimmer L
Eur J Cancer; 2021 May; 148():395-404. PubMed ID: 33789203
[TBL] [Abstract][Full Text] [Related]
5. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).
Ferguson SD; Bindal S; Bassett RL; Haydu LE; McCutcheon IE; Heimberger AB; Li J; O'Brien BJ; Guha-Thakurta N; Tetzlaff MT; Tawbi H; Davies MA; Glitza IC
J Neurooncol; 2019 May; 142(3):499-509. PubMed ID: 30847840
[TBL] [Abstract][Full Text] [Related]
6. Advances in the Diagnosis and Treatment of Leptomeningeal Disease.
Sharma A; Low JT; Kumthekar P
Curr Neurol Neurosci Rep; 2022 Jul; 22(7):413-425. PubMed ID: 35588045
[TBL] [Abstract][Full Text] [Related]
7. Leptomeningeal Metastasis: A Review of the Pathophysiology, Diagnostic Methodology, and Therapeutic Landscape.
Nguyen A; Nguyen A; Dada OT; Desai PD; Ricci JC; Godbole NB; Pierre K; Lucke-Wold B
Curr Oncol; 2023 Jun; 30(6):5906-5931. PubMed ID: 37366925
[TBL] [Abstract][Full Text] [Related]
8. Comparison of CSF cytology and spinal magnetic resonance imaging in the detection of leptomeningeal disease in pediatric medulloblastoma or primitive neuroectodermal tumor.
Fouladi M; Gajjar A; Boyett JM; Walter AW; Thompson SJ; Merchant TE; Jenkins JJ; Langston JW; Liu A; Kun LE; Heideman RL
J Clin Oncol; 1999 Oct; 17(10):3234-7. PubMed ID: 10506624
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy for leptomeningeal disease in breast cancer.
Bartsch R; Jerzak KJ; Larrouquere L; Müller V; Le Rhun E
Cancer Treat Rev; 2024 Jan; 122():102653. PubMed ID: 38118373
[TBL] [Abstract][Full Text] [Related]
10. Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases.
Khaled ML; Tarhini AA; Forsyth PA; Smalley I; Piña Y
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980770
[TBL] [Abstract][Full Text] [Related]
11. Leptomeningeal Disease and the Evolving Role of Molecular Targeted Therapy and Immunotherapy.
Thomas KH; Ramirez RA
Ochsner J; 2017; 17(4):362-378. PubMed ID: 29230121
[TBL] [Abstract][Full Text] [Related]
12. Intrathecal therapy for the management of leptomeningeal metastatic disease: a scoping review of the current literature and ongoing clinical trials.
Palmisciano P; Watanabe G; Conching A; Ogasawara C; Vojnic M; D'Amico RS
J Neurooncol; 2022 Oct; 160(1):79-100. PubMed ID: 35999434
[TBL] [Abstract][Full Text] [Related]
13. Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease.
Dan X; Huang M; Sun Z; Chu X; Shi X; Chen Y
Front Oncol; 2024; 14():1344829. PubMed ID: 38665955
[TBL] [Abstract][Full Text] [Related]
14. Durable complete remission of leptomeningeal melanoma by intrathecal methotrexate maintained with systemic ipilimumab.
Dietrich C; Salzmann M; Steinbrecher A; Herbst R; Hassel JC
Immunotherapy; 2021 Sep; 13(13):1079-1083. PubMed ID: 34259028
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
[TBL] [Abstract][Full Text] [Related]
16. Latest clinical research in leptomeningeal disease (LMD)-a narrative review.
Chan AW; Wong HCY; Taphoorn M; Dirven L; Le Rhun E; Soliman H; Oldenburger E; Raman S; Vassiliou V; Bonomo P; Koller M; Marta GN; Rembielak A; Lee SF; Chow E; Simone CB
Ann Palliat Med; 2023 Nov; 12(6):1215-1231. PubMed ID: 37953219
[TBL] [Abstract][Full Text] [Related]
17. Radiation Therapy in the Management of Leptomeningeal Disease From Solid Tumors.
Barbour AB; Kotecha R; Lazarev S; Palmer JD; Robinson T; Yerramilli D; Yang JT
Adv Radiat Oncol; 2024 Feb; 9(2):101377. PubMed ID: 38405313
[TBL] [Abstract][Full Text] [Related]
18. Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution.
Mandel JJ; Yust-Katz S; Cachia D; Wu J; Liu D; de Groot JF; Yung AW; Gilbert MR
J Neurooncol; 2014 Dec; 120(3):597-605. PubMed ID: 25168214
[TBL] [Abstract][Full Text] [Related]
19. Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease.
Law V; Smalley I; Evernden BR; Baldwin M; Smalley KSM; Forsyth PA
J Vis Exp; 2024 Mar; (205):. PubMed ID: 38619274
[TBL] [Abstract][Full Text] [Related]
20. Leptomeningeal disease in glioblastoma: endgame or opportunity?
Akmal S; Ginalis EE; Patel NV; Aiken R; Dicpinigaitis AJ; Hanft SJ
J Neurooncol; 2021 Nov; 155(2):107-115. PubMed ID: 34623599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
